madrigal-pharma

Inventiva

This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

Mirum Pharmaceuticals

This biopharmaceutical company develops and commercialises therapies for rare liver diseases, primarily treating children and adults with cholestatic and metabolic conditions.

Intercept Pharmaceuticals

This company develops and commercialises small molecule therapeutics to treat chronic liver diseases for healthcare providers and patients.

Cymabay Therapeutics

This biopharmaceutical company develops oral therapies for patients with chronic liver diseases and metabolic disorders including primary biliary cholangitis.

AKRO

This company develops injectable medicines to treat patients with serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis.

Metabolys

This biopharmaceutical company develops oral small molecules to treat metabolic diseases, specifically non-alcoholic steatohepatitis and type 2 diabetes, for the global healthcare market.

Altimmune

This biopharmaceutical company develops peptide-based therapeutics for patients with obesity and liver diseases, including metabolic dysfunction-associated steatohepatitis and alcohol-associated liver disease.